Predictor of outcome of hyperthyroidism due to graves disease : Serum trhodothyronine/thyroxine ratio

Journal of Association of Physicians of India

Volumn 44, Issue 2, 1996, Pages 98-101

  Khanna, C M ^a   Ravi Shankar, L ^a   Jaggi, C B ^a   Bansal, J K ^a   Chugh, P ^a  

^a INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; BIOLOGICAL MARKER; LIOTHYRONINE; THYROXINE;

ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; EVALUATION; FEMALE; GRAVES DISEASE; HUMAN; MALE; MIDDLE AGED; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; AGED; ANTITHYROID AGENTS; BIOLOGICAL MARKERS; EVALUATION STUDIES; FEMALE; GRAVES DISEASE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SENSITIVITY AND SPECIFICITY; THYROXINE; TREATMENT OUTCOME; TRIIODOTHYRONINE;

EID: 0030072305     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Alexander WD, Harden RM, Shimmins J. Thyroidal suppression by triiodothyronine as a guide to duration of treatment of thyrotoxicosis with antithyroid drugs Lancet 1966; 2 : 1041.
2. Slinger land DW, Belton A, Burrows A. Long term antithyroid treatment in hyperhyroidism. JAMA 1979; 242 : 2408.
3. Yamada T, Koizumi Y, Sato A et al. Reappraisal of the 3,5 triiodothyronine suppression test in the prediction of long term outcome of antithyroid drug therapy in patients with hyperthyroid Grave's disease. J Clin Endocrinol Matab 1978; 46 : 747.
4. Ulter RP, Van Herb AJ. Effects of therapy on serum thyroglobulin levels in patinets with Grave's disease. J Clin Endocrinol Metab 1978; 46 : 747.
5. Davies TF, Yeo PPB, Evered DC, et al. Value of Thyroid stimulating antibody determination in predicting short term thyrotoxic relapse in Grave's disease. Lancet 1977; 1 : 1181.
6. Fenzi G, Hashizume K, Roudebush CP, DeGroot LJ. Changes in Thyroid-stimulating antibody determination in predicting short term thyrotoxic relapse in Grave's disease. Lancet 1979; 48 : 572.
7. Zakarija M, Mckenzie JM, Bonavoc K. Clinical significance of assay of thyroid stimulating antibody in Grave's disease. Ann Intern Med 1980; 93 : 28.
8. Irvine WJ, Gray RD, Morris PJ, Ting A. Correlation of HLA and thyroid antibodies with clinical course of thyrotoxicosis treated with antithyroid drugs. Lancet 1977; 2 : 898.
9. McGregor AM, Rees Smith BR, Hall R, et al. Prediction of relapse in hyperthyroid Grave's disease. Lancet 1980; 1 : 1101.
10. Takamatsu J, Sugawara M, Kuma K, et al. Ratio of serum triiodo thyronine to thyroxine and the prognosis of triiodothyronine predominent Grave's disease. Ann Intern Med 1984; 100 : 372.
11. Amino M, Yabu Y, Mori K, Kumohara Y, Miyai K. Differentiation of thyrotoxicosis induced by thyroid destruction from Grave's disease. Lancet 1978; 2 : 344.
12. Freer MA, Kammer H, Bouma DJ. Short term antithyroid drug therapy for the thyrotoxicosis of Grave's disease N Engl J Med 1977; 297 : 173.
13. Shizume K, Lrie M, Nagataki S, et al. Long term result of antithyroid drug therapy for Grave's disease - follow up after more than 5 years. Endocrinol Jpn 1970; 17 : 327.
14. Lauerberg P, Mechanisms governing the relative proportions of thyroxine and 3,5,3 - triiodo thyronine in thyroid secretion. Metabolism 1984; 33 : 379.
15. Ishii H, Inada M, Tanaka K, et al. Triodo thyronine generation from thyroxine in human thyroid: enhanced conversion in Grave's thyroid tissue. J Clin Endocrinol Metab 1981; 52 : 1211-7.